How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Accurate and rapid diagnosis is crucial for tuberculosis control by ensuring a timely start to treatment and reducing transmission. In 2012, almost one third of tuberculosis cases were not diagnosed and/or reported to national tuberculosis programmes (NTPs), and <25% of estimated incident multidrug-resistant (MDR) cases were diagnosed [1]. Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA), a nucleic acid amplification test, was recommended in 2010 by the World Health Organization (WHO) for detection of HIV-associated pulmonary tuberculosis and rifampicin resistance [2]. In 2013, the test was recommended for detection of paediatric tuberculosis and some forms of extrapulmonary tuberculosis (EPTB), as well as an initial test to replace smear microscopy [3]. Xpert MTB/RIF implementation is mainly donor-funded, focused on DST and is not widely used outside South Africa We are grateful to all NTP staff and respondents who completed the surveys and answered our follow-up questions. We are also grateful to Claudia Denkinger (Foundation for Innovative New Diagnostics, Geneva, Switzerland), Sandra Kik (KNCV Tuberculosis Foundation, The Hague, The Netherlands) and Pamela Chedore (independent laboratory consultant, Toronto, Canada) for useful input on the survey design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF
Weyer, K., Mirzayev, F., Migliori, G. B., Van Gemert, W., D'Ambrosio, L., Zignol, M., Floyd, K., Centis, R., Cirillo, D. M., Tortoli, E., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00157212 · Cited by 256
Cited by
Kyu, H. H., Maddison, E. R., Henry, N. J., Ledesma, J. R., Wiens, K. E., Reiner, R., Biehl, M. H., Shields, C., Osgood-Zimmerman, A., Ross, J. M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30625-x · Cited by 437
Albert, H., Nathavitharana, R. R., Isaacs, C., Pai, M., Denkinger, C. M., & Boehme, C. C. (2016) · European Respiratory Journal · doi:10.1183/13993003.00543-2016 · Cited by 300
Self-citationThe South African tuberculosis care cascade: Estimated losses and methodological challenges
Naidoo, P., Theron, G., Rangaka, M. X., Chihota, V. N., Vaughan, L., Brey, Z. O., & Pillay, Y. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix335 · Cited by 238
“5 million cartridges procured globally to mid-2014) [45] and the national roll-out of Xpert, <60% of individuals with presumptive tuberculosis received an Xpert test.”
BackgroundTuberculosis Diagnostics in 2015: Landscape, Priorities, Needs, and Prospects
Pai, M., & Schito, M. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu803 · Cited by 193
Self-citationRahman, M. T., Codlin, A. J., Rahman, M. M., Nahar, A., Reja, M., Islam, T., Qin, Z. Z., Khan, M. A. S., Banu, S., & Creswell, J. (2017) · European Respiratory Journal · doi:10.1183/13993003.02159-2016 · Cited by 66
Self-citation
Metadata
- Authors
- Qin, Z. Z., Pai, M., Van Gemert, W., Sahu, S., Ghiasi, M., & Creswell, J.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2014-10-30
- Volume
- 45
- Issue
- 2
- Pages
- 549-554
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2102683194
- Cited by
- 58
- References
- 1
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? https://app.cochat.ai/papers/10.1183/09031936.00147714
- The paper
- Qin, Z. Z., Pai, M., Van Gemert, W., Sahu, S., Ghiasi, M., & Creswell, J. (2015). How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? European Respiratory Journal. https://doi.org/10.1183/09031936.00147714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.